BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 20615102)

  • 1. Effectiveness of exenatide in Asian Indians in a clinical care setting.
    Sudhakaran C; Fathima M; Anjana RM; Unnikrishnan RI; Mohan V
    Diabetes Technol Ther; 2010 Aug; 12(8):613-8. PubMed ID: 20615102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
    Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
    Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
    Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
    Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.
    Inagaki N; Atsumi Y; Oura T; Saito H; Imaoka T
    Clin Ther; 2012 Sep; 34(9):1892-908.e1. PubMed ID: 22884767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Summaries for patients. Exenatide or insulin glargine for suboptimally controlled diabetes?
    Ann Intern Med; 2005 Oct; 143(8):I30. PubMed ID: 16230718
    [No Abstract]   [Full Text] [Related]  

  • 7. Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration.
    Buse JB; Han J; Miller S; MacConell L; Pencek R; Wintle M
    Curr Med Res Opin; 2014 Jul; 30(7):1209-18. PubMed ID: 24621255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting.
    Pawaskar M; Li Q; Hoogwerf BJ; Reynolds MW; Faries D; Engelman W; Bruhn D; Bergenstal RM
    Diabetes Obes Metab; 2012 Jul; 14(7):626-33. PubMed ID: 22321776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
    Yki-Järvinen H; Dressler A; Ziemen M;
    Diabetes Care; 2000 Aug; 23(8):1130-6. PubMed ID: 10937510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of sitagliptin in asian Indian patients with type 2 diabetes-an Indian tertiary diabetes care center experience.
    Sudhakaran C; Kishore U; Anjana RM; Unnikrishnan R; Mohan V
    Diabetes Technol Ther; 2011 Jan; 13(1):27-32. PubMed ID: 21175268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
    Buse JB; Bergenstal RM; Glass LC; Heilmann CR; Lewis MS; Kwan AY; Hoogwerf BJ; Rosenstock J
    Ann Intern Med; 2011 Jan; 154(2):103-12. PubMed ID: 21138825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus.
    Levin PA; Mersey JH; Zhou S; Bromberger LA
    Endocr Pract; 2012; 18(1):17-25. PubMed ID: 21742605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
    Mullins P; Sharplin P; Yki-Jarvinen H; Riddle MC; Haring HU
    Clin Ther; 2007 Aug; 29(8):1607-19. PubMed ID: 17919543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of patient and treatment characteristics on glycemic control and hypoglycemia in patients with type 2 diabetes initiated to insulin glargine or NPH: A post hoc, pooled, patient-level analysis of 6 randomized controlled trials.
    Porcellati F; Lin J; Lucidi P; Bolli GB; Fanelli CG
    Medicine (Baltimore); 2017 Feb; 96(5):e6022. PubMed ID: 28151905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin glargine improves glycemic control and quality of life in type 2 diabetic patients on hemodialysis.
    Toyoda M; Kimura M; Yamamoto N; Miyauchi M; Umezono T; Suzuki D
    J Nephrol; 2012; 25(6):989-95. PubMed ID: 22307438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.
    Bunck MC; Diamant M; Cornér A; Eliasson B; Malloy JL; Shaginian RM; Deng W; Kendall DM; Taskinen MR; Smith U; Yki-Järvinen H; Heine RJ
    Diabetes Care; 2009 May; 32(5):762-8. PubMed ID: 19196887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy.
    Karagianni P; Polyzos SA; Kartali N; Zografou I; Sambanis C
    Adv Med Sci; 2013; 58(1):38-43. PubMed ID: 23640946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of exenatide twice daily compared to insulin lispro added to basal insulin in Latin American patients with type 2 diabetes: A retrospective analysis of the 4B trial.
    de Lapertosa SB; Frechtel G; Hardy E; Sauque-Reyna L
    Diabetes Res Clin Pract; 2016 Dec; 122():38-45. PubMed ID: 27776251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland.
    Brändle M; Erny-Albrecht KM; Goodall G; Spinas GA; Streit P; Valentine WJ
    Int J Clin Pharmacol Ther; 2009 Aug; 47(8):501-15. PubMed ID: 19640359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients.
    Pan CY; Sinnassamy P; Chung KD; Kim KW;
    Diabetes Res Clin Pract; 2007 Apr; 76(1):111-8. PubMed ID: 17011662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.